Preliminary results from a phase 2a trial involving 71 patients suggest that a new agent, discovered and designed with artificial intelligence assistance, is safe and effective for the treatment of idiopathic pulmonary fibrosis.
Artificial intelligence is rapidly inventing new drugs for diseases from Parkinson's disease and antibiotic-resistant superbugs to rare lung conditions.
Artificial intelligence is rapidly inventing new drugs for diseases from Parkinson's disease and antibiotic-resistant superbugs to rare lung conditions.
The Batch AI News and Insights: AI-native software engineering teams operate very differently than traditional teams.
IsoDDE doubles AlphaFold 3 on hard benchmarks and beats physics-based gold standards. But no AI drug has FDA approval. What $4B in pharma deals actually mean.